Health: Clinical Success Against Multiple Sclerosis – Health


Novartis asserts on Friday that he has found a superiority of its experimental treatment against multiple sclerosis, ofatumumab, on the Aubagio (teriflunomide) of its Spanish rival Sanofi.

Clinical studies "Asclepios" I and II have in particular demonstrated a reduction in the annualized rate of relapse in patients with recurrent-remitting form of the disease, allowing these research components to reach their primary endpoint.

Several secondary criteria were also implemented, starting with a non-detailed slowdown in the progression of disability. The multinational intends to make a more precise point on the results of these studies at the next congress of the European Committee for Treatment and Research Against Multiple Sclerosis (Ectrims), which will be held from 11 to 13 September in Stockholm .

Marketing authorization

Talks will then be held with various health policemen by the end of the year for marketing authorization. In the event of approval, ofatumumab could become the first therapy for B cells that a large population of patients could autonomously administer at home, said a statement.

The Rhine laboratory acquired the rights to ofatumumab from Denmark's Genmab and its UK partner GlaxoSmithKline (GSK) in December 2015, with up to $ 1 billion in initial and milestone payments. The substance is already marketed in the field of oncology under the name Arzerra. (Ps / nxp)

Created: 30.08.2019, 08:24

Source link


Please enter your comment!
Please enter your name here

four × five =